292 related articles for article (PubMed ID: 36761724)
1. Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer.
Zhang X; Xu Z; Dai X; Zhang X; Wang X
Front Immunol; 2023; 14():1104860. PubMed ID: 36761724
[TBL] [Abstract][Full Text] [Related]
2. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
Bassani-Sternberg M; Digklia A; Huber F; Wagner D; Sempoux C; Stevenson BJ; Thierry AC; Michaux J; Pak H; Racle J; Boudousquie C; Balint K; Coukos G; Gfeller D; Martin Lluesma S; Harari A; Demartines N; Kandalaft LE
Front Immunol; 2019; 10():1832. PubMed ID: 31440238
[TBL] [Abstract][Full Text] [Related]
4. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
6. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
7. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
[TBL] [Abstract][Full Text] [Related]
8. Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications.
Tang L; Zhang R; Zhang X; Yang L
Front Oncol; 2021; 11():701777. PubMed ID: 34381724
[TBL] [Abstract][Full Text] [Related]
9. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
10. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
[TBL] [Abstract][Full Text] [Related]
11. Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities.
Fu C; Ma T; Zhou L; Mi QS; Jiang A
Immunol Invest; 2022 Nov; 51(8):2133-2158. PubMed ID: 35946383
[TBL] [Abstract][Full Text] [Related]
12. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
13. Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine.
Morisaki S; Onishi H; Morisaki T; Kubo M; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Tsujimura K; Yoshimura S; Yew PY; Kiyotani K; Nakamura Y; Nakamura M; Kitazono T; Morisaki T
Front Immunol; 2023; 14():1223331. PubMed ID: 37881436
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
[TBL] [Abstract][Full Text] [Related]
16. Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
Schmitt S; Tahk S; Lohner A; Hänel G; Maiser A; Hauke M; Patel L; Rothe M; Josenhans C; Leonhardt H; Griffioen M; Deiser K; Fenn NC; Hopfner KP; Subklewe M
Front Immunol; 2020; 11():602802. PubMed ID: 33281829
[TBL] [Abstract][Full Text] [Related]
17. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
18. α-d-Glucose-1,6-Biphosphate Induces Dendritic Cell Homing to Enhance the Antitumor Effect of Neoantigen Vaccines.
Zhang R; Tang L; Wang Y; Li Q; Yang L
J Immunol; 2023 Sep; 211(6):932-943. PubMed ID: 37556117
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
20. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Chen X; Yang J; Wang L; Liu B
Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
